SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community debates potential short-term dips versus long-term bullish prospects, with some bracing for a possible weekend correction. Discussions include technical analysis, predictions of future price movements, and the impact of external factors like potential government regulations and macroeconomic conditions. Some traders are closely watching altcoins and memecoins while also weighing investment strategies around Bitcoin.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amidst a broad crypto dip, sparking discussions about market manipulation and potential buying opportunities. The community is weighing the impact of upcoming ETFs and regulatory developments against concerns about price suppression and the token's long-term potential. Some traders are looking for a dip to accumulate more XRP, while others are losing faith.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as traders discuss recent price volatility and potential manipulation, with some seeing buying opportunities amidst the overnight dips. Community members are weighing in on technical analysis, potential support levels, and the impact of large players. The conversation also includes speculation about upcoming catalysts and long-term price predictions for ETH.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending as community members discuss a potential short squeeze, given the high short interest. However, some are pointing to insider selling and debating the company's valuation relative to its Bitcoin holdings. Sentiment is further influenced by potential AI ventures, broader market factors, and comparisons to other mining stocks.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members discuss its recent surge, potential for further growth, and comparisons to other quantum computing stocks like $QUBT and $IONQ. Some traders are taking profits, while others remain bullish, citing government contracts and long-term potential, while some express concerns about high valuation.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending as investors monitor its correlation with Ethereum's price movements, particularly overnight dips, and anticipate potential strategic ETH acquisitions by the company. The community is actively discussing dilution possibilities and speculating on the impact of Tom Lee's investment strategies, while also eyeing potential mergers within the crypto space. Bullish sentiment persists, with some traders anticipating a breakout and significant gains, driven by the company's growing ETH holdings and positive technical indicators.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo ($OKLO) is trending due to a recent price target increase from Wedbush, fueling both excitement and skepticism. While some see it as a leader in a $10 trillion industry akin to early NVDA, others believe it's overvalued with no current product or revenue, drawing comparisons to meme stocks and potential future dilution. The community is debating its long-term potential versus short-term hype, with concerns about insider selling and an upcoming offering.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Metsera Inc

Metsera is trending amid reports of a potential acquisition by Pfizer for $7.3 billion, fueling discussions about the increasing value of obesity and MASH-focused drug companies. The community speculates about potential competing offers and the implications for other players in the sector like $VKTX and $ALT. Some traders are focused on upcoming data releases, anticipating significant stock movement.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK.X is trending as community members rally around its satirical take on traditional retirement plans, with many expressing excitement about its potential. Fueling the conversation is the coin's recent growth and strong community engagement, as well as its positioning as an alternative to the conventional 401k. The coin is associated with the Solana blockchain.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending due to news of a significant private placement, leading to community discussions about dilution and its potential impact. Some traders are pointing out this could lead to a pullback, while others believe it signals continued momentum in the quantum computing sector. The community is also weighing the news against the backdrop of broader interest in quantum computing and potential government investment.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer is reportedly preparing to buy weight-loss biotech Metsera in a deal that could be worth as much as $7.3 billion.The New York-based drugmaker would apparently pay $47.50 a share upfront and another $22.50 tied to milestones, a sharp premium to Metsera’s recent price of $33.32. An announcement could come as early as Monday, barring last-minute delays, according to a Financial Times&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/aee4a71c-7ad6-4cde-852f-720a97542fac">report</a>,&nbsp;which cited two people familiar with the matter.The move comes after Pfizer scrapped its own obesity drug candidate, danuglipron, earlier this year. Metsera, which is listed in one of 2025’s biggest biotech IPOs, has drawn interest across the sector with MET-097i, a GLP-1 therapy that produced 11.3% weight loss over 12 weeks in a mid-stage trial.&nbsp;The company is also developing a monthly version of the shot, an amylin-based treatment aimed at avoiding muscle loss, and an oral pill. Pfizer shares, now worth about half their 2021 pandemic peak, closed Friday at $24, valuing the company at $136 billion.&nbsp;CEO Albert Bourla has been under pressure to reignite growth, with Pfizer’s last major deal being the $43 billion purchase of cancer drugmaker Seagen in 2023. A Metsera acquisition would put it in direct competition with Eli Lilly and Novo Nordisk, whose blockbuster GLP-1 drugs Zepbound and Wegovy are expanding into pill form.On Stocktwits, retail sentiment for both Pfizer and Metsera was ‘bullish’, with message volume ‘normal’ for Pfizer and ‘high’ for Metsera.One user&nbsp;labeled the reported deal value&nbsp;a “lousy premium” to Metsera’s recent trading levels and argued the company’s management may be selling too cheaply. The user added that Pfizer may have avoided a bigger gamble on Viking Therapeutics ahead of late-stage trials.<stembedurl>https://stocktwits.com/biolover/message/629465706</stembedurl>Another bullish user said that the acquisition could ultimately be seen as an $80-per-share buyout opportunity.<stembedurl>https://stocktwits.com/vu_jade/message/629466433</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> has declined 4.6% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MTSR">Metsera’s stock</a> has risen 25.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Stock Draws Focus On Report Of $7.3B Deal Plan For Metsera Buyout As Obesity Drug Race With Lilly, Novo Heats Up

Pfizer is pushing into the booming weight-loss market after its own drug setback, as rivals Eli Lilly and Novo Nordisk lead the field.

Equity

Recent Price Trend in Metsera Inc. (MTSR) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Metsera Inc. (MTSR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

The mean of analysts' price targets for Metsera Inc. (MTSR) points to a 55.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why  

Metsera Inc. (MTSR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 89.7% in Metsera Inc. (MTSR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Shares of Metsera, Inc. (MTSR) soared 12% on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/09/3095726/0/en/Metsera-Announces-Positive-Phase-1-Data-of-First-in-Class-Once-Monthly-Amylin-Candidate-MET-233i.html">announced</a> positive topline data from an early-stage clinical trial evaluating its experimental drug in helping patients lose weight.The company stated that MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.MET-233i is an ultra-long-acting, subcutaneously injectable monthly amylin analog. Amylin analogs work by mimicking the effects of amylin, a hormone co-secreted with insulin from the pancreas.Amylin helps regulate blood glucose levels by slowing down gastric emptying, reducing appetite, and inhibiting glucagon secretion.Steve Marso, Chief Medical Officer of Metsera, said that the company observed five-week body weight loss comparable to that of leading GLP-1-based medicines.In the trial, MET-233i was evaluated at single doses ranging from 0.15 mg to 2.4 mg, and multiple doses from 0.15 mg to 1.2 mg, administered once weekly over five weeks without titration.Based on the positive topline data, Metsera is now rapidly advancing MET-233i as a monotherapy and in combination with its GLP-1 candidate MET-097i.The company expects data from a trial evaluating MET-233i as a monotherapy in late 2025, and from a trial assessing the co-administration of MET-233i and MET-097i by year-end or early 2026.The weight loss drug market is currently dominated by GLP-1 drugs from Novo Nordisk and Eli Lilly.Bank of America opined that the monotherapy data "looks competitive," though it "seems more likely that amylin+GLP1 combinations will be more important."The firm reiterated a ‘Buy’ rating and $38 price target on the stock.On Stocktwits, retail sentiment around Metsera jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_09_at_2_15_27_PM_png_7a04a2cbb2.webp" alt="MTSR's Sentiment Meter and Message Volume as of 1:40 p.m. ET on June 9, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>MTSR's Sentiment Meter and Message Volume as of 1:40 p.m. ET on June 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> is up by about 17% since its debut on the Nasdaq in late January.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-made-no-drug-price-pledges-in-meeting-with-trump-report/chlEkvDRbyS">Pfizer CEO Reportedly Says Company Made No Drug Price Pledges In Meeting With Trump Administration: Retail Sentiment Improves</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug:  Retail Chatter Explodes

The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.

Wall Street bullish on Metsera following January IPO on obesity drug pipeline

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a potential acquisition target for larger biopharma firms looking to enter the obesity market.

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$34.30
Prev Close	$35.90
Open	$36.21
Dividend Yield	N/A
50-Day Moving Average	$35.57
Beta	2.00
Avg. Volume	1.39M
PE Ratio	N/A

52-Week High	$47.40
52-Week Low	$12.30
Market Capitalization	$3.5B
EPS (Annual)	-$1.99
Price to Book	7.78
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MTSR
Metsera Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MTSR News

MTSR Metsera Inc